FY2019 Earnings Estimate for Paratek Pharmaceuticals Inc Issued By Gabelli (PRTK)

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) – Gabelli lowered their FY2019 earnings estimates for shares of Paratek Pharmaceuticals in a report issued on Tuesday, May 21st. Gabelli analyst K. Kedra now anticipates that the specialty pharmaceutical company will earn ($4.55) per share for the year, down from their prior forecast of ($4.50). Gabelli also issued estimates for Paratek Pharmaceuticals’ FY2020 earnings at ($3.85) EPS, FY2021 earnings at ($2.60) EPS, FY2022 earnings at ($1.05) EPS and FY2023 earnings at $0.05 EPS.

Several other research analysts have also commented on the stock. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 15th. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target (down from $17.00) on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. LADENBURG THALM/SH SH reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. ValuEngine lowered shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Finally, Canaccord Genuity set a $25.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $22.25.

NASDAQ PRTK opened at $4.22 on Thursday. Paratek Pharmaceuticals has a one year low of $4.02 and a one year high of $12.30. The company has a quick ratio of 13.95, a current ratio of 14.06 and a debt-to-equity ratio of 14.48. The stock has a market capitalization of $142.31 million, a PE ratio of -1.18 and a beta of 1.52.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.19) by $0.09. Paratek Pharmaceuticals had a negative net margin of 642.70% and a negative return on equity of 232.61%. The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.89 million.

A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in Paratek Pharmaceuticals by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 138,282 shares of the specialty pharmaceutical company’s stock valued at $710,000 after purchasing an additional 1,906 shares during the period. Annex Advisory Services LLC boosted its stake in Paratek Pharmaceuticals by 15.3% during the 4th quarter. Annex Advisory Services LLC now owns 15,100 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,000 shares during the period. Teton Advisors Inc. boosted its stake in Paratek Pharmaceuticals by 1.9% during the 1st quarter. Teton Advisors Inc. now owns 110,000 shares of the specialty pharmaceutical company’s stock valued at $590,000 after purchasing an additional 2,000 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in Paratek Pharmaceuticals by 15.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 18,867 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 2,500 shares during the period. Finally, Swiss National Bank boosted its stake in Paratek Pharmaceuticals by 6.6% during the 1st quarter. Swiss National Bank now owns 49,800 shares of the specialty pharmaceutical company’s stock valued at $267,000 after purchasing an additional 3,100 shares during the period. 73.79% of the stock is owned by hedge funds and other institutional investors.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Read More: Index Funds

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.